Name (Synonyms) | Correlation |
---|
There is one clinical trial.
It is supposed to monitor hypertensive patients who are infected or have clinical manifestations of COVID-19 for 1 month after the onset of the disease. Three groups will be considered: 1. receiving ACE inhibitors 2. receiving ARBs 3. receiving DIR.
Description: BP one week before COVID-19 infection and 3 weeks follow-up after COVID-19 onset
Measure: BP (hypertensive efficacy) Time: 4 weeksDescription: features of disease course: number of patients and duration of fever (above 37.2C), duration of cough (days), duration of throat pain (days), headache (days), nausea or vomiting (days), diarrhea (days), myalgia or arthalgia (days), and numder of patients who need hospital and intensive care unit
Measure: COVID-19 course Time: 3 weeks